Overview of Albezol

Property	Description
Active ingredient	Albendazole (INN)
Form	Tablet, Oral Suspension, Chewable Tablet
Pharmacological class	Anthelmintic Drug / Antiprotozoal Agent
General Purpose	To eliminate parasitic and protozoal infections
Origin	Synthetic Benzimidazole Derivative

What Type of Medicine is Albezol?

Albezol is a prescription-only medicine that is fundamentally classified as a broad-spectrum anthelmintic drug, belonging to the chemical family of Benzimidazole carbamates. Its active ingredient is Albendazole (INN), a synthetic compound derived from the benzimidazole structure. This classification means the substance is specifically designed to eliminate parasitic worms (helminths) and is also categorized as an antiprotozoal agent. Albendazole is recognized as being authorized for use against a broad range of parasitic infections, reflecting its versatile action in human medicine.

Composition, Forms, and General Therapeutic Purpose

The core composition of this medicine is the single active ingredient Albendazole. This pharmaceutical preparation is administered orally (by mouth) and is widely available in different dosage forms, including a solid tablet, a liquid oral suspension for easier consumption by younger patients, and a chewable tablet. As an anthelmintic agent, the general therapeutic purpose of Albezol is to address and clear various parasitic infections and protozoal infections in the body, such as those that affect the intestinal tract. Furthermore, Albendazole has a documented role and significance in global public health. This profile underscores the drug's reliable ability to act as a Larvicidal, Ovicidal, and Vermicidal agent, destroying the parasitic adults, larvae, and eggs.

What side effects are possible with Albezol?

Possible side effects and safety information

Albezol (Albendazole) has an established safety profile documented in regulatory labeling, with adverse reactions generally classified by frequency and the organ system affected. The most frequently observed side effects are classified as Very Common or Common and typically involve the central nervous system or gastrointestinal tract, such as headache, abdominal pain, nausea, and vomiting. Reversible increases in hepatic enzyme levels (transaminases) are also Very Common, often normalizing after discontinuation.

The primary regulatory focus is on the potential for serious adverse reactions affecting two key body systems. These include Hepato-biliary disorders, which encompass cases of hepatitis and rare instances of acute liver failure, and Blood and Lymphatic System disorders, including rare but severe events like bone marrow suppression, pancytopenia, and aplastic anemia.

Population-Specific Safety Constraints

The official safety information includes critical constraints for specific patient populations. The medicine is generally contraindicated during pregnancy due to the risk of fetal harm, and women of childbearing potential are required to use effective contraception. Patients with pre-existing hepatic impairment are identified as having an increased risk of hepatotoxicity and bone marrow suppression. Furthermore, the label notes that neurological symptoms, such as increased intracranial pressure, may appear soon after treatment initiation for neurocysticercosis, which is related to the inflammatory response from parasite death.

Overdose and Emergency Response

The official regulatory profile for an Albendazole overdose focuses on the potential for severe, systemic toxicity, primarily impacting the hematopoietic and hepatic systems. Overdose severity is classified as potentially life-threatening due to the documented risk of profound bone marrow suppression.

Documented manifestations in cases of severe exposure include significant blood cell disorders such as pancytopenia, agranulocytosis, and aplastic anemia, which have been associated with reported fatalities. Other clinical signs involve elevated hepatic enzymes (transaminases), acute liver failure in post-marketing reports, headache, and reversible alopecia.

Official labeling notes that patients with pre-existing liver disease or hepatic echinococcosis may have an increased risk for these severe hematological outcomes.

Management involves symptomatic treatment and supportive care as no specific antidote is known. Emergency response is mandated by regulatory authorities: Seek immediate medical attention or call emergency services if severe symptoms such as collapse, seizure, or difficulty breathing occur. Furthermore, therapy must be discontinued if laboratory results show clinically significant decreases in blood cell counts or if liver enzymes exceed twice the upper limit of normal, a regulatory requirement for managing toxicity.

Therapeutic Uses of Albezol

Quick Facts: Albezol Uses

Supports the management of parasitic infections caused by certain tapeworms and other worms.
Used in the therapeutic plan for neurocysticercosis, which involves the nervous system.
Prescribed for the treatment of cystic hydatid disease affecting areas such as the liver, lung, and peritoneum.

Albezol (Albendazole) is a prescription medication designated for addressing specific parasitic infections. The primary approved uses relate to two conditions caused by larval tapeworms. It is an established component of the therapeutic approach for neurocysticercosis, which stems from the larval form of the pork tapeworm (Taenia solium).

The medication is also utilized in the management of cystic hydatid disease, which occurs when the larval form of the dog tapeworm (Echinococcus granulosus) affects the liver, lungs, or lining of the abdomen. In some cases, healthcare providers may also prescribe Albezol for other types of parasitic worm infections, as part of a patient's overall treatment plan, including microsporidiosis.

Eligibility and Restrictions for Use

Who Can and Cannot Use Albezol (Official Regulatory Information)

The eligibility for Albezol (Albendazole) is strictly defined by regulatory documents, which classify patients into three main categories: contraindicated, restricted, and eligible under specific conditions.

Contraindications and Prohibited Use

Hypersensitivity: Strictly contraindicated for any patient with a known hypersensitivity to albendazole or to other benzimidazole class compounds.
Pregnancy: Use is prohibited for pregnant women due to the documented risk of fetal harm.

Conditional and Restricted Eligibility

Females of Reproductive Potential: Eligibility is conditional upon providing a negative pregnancy test and using effective contraception during and after treatment.
Lactation: Breastfeeding must be discontinued during therapy and for a defined period after the final dose.
Organ Status: Patients with pre-existing liver disease or a predisposition to myelosuppression (bone marrow disorders) are eligible only under the condition of mandatory, frequent monitoring of liver enzymes and blood cell counts.

Age-Related Limitations

Children: Use in children under six years of age is not recommended due to limited clinical experience supporting safety in this young population.
Older Adults (Geriatric): Experience in this population is limited, and caution is necessary if hepatic dysfunction is evident. Renal impairment does not typically require dosage adjustment.

What should I know about interactions with other medicines?

The regulatory profile for Albezol (Albendazole) is defined by documented pharmacokinetic, pharmacodynamic, and substance-related interaction patterns.

Official Exposure-Altering Interactions

Specific medicines are documented to alter the systemic exposure of the active metabolite, Albendazole sulfoxide:

Increase in Plasma Concentration: Co-administration with Praziquantel increases the active metabolite's mean maximum plasma concentration and AUC by approximately 50%. Similar increases are documented with Dexamethasone (56% increase in trough concentrations) and Cimetidine (approximately 2-fold increase in bile/cystic fluid concentrations).
Decrease in Plasma Concentration: Anticonvulsants such as Phenytoin and Fosphenytoin are noted to decrease the plasma levels of the active metabolite by increasing its metabolism.
Enzyme Induction: Albendazole is documented to induce the CYP1A enzyme, suggesting a need for monitoring the plasma concentrations of certain co-administered substrates like Theophylline.

Pharmacodynamic and Substance Restrictions

Additive Risk: A clinically significant pharmacodynamic risk is the documented potential for additive bone marrow suppression when co-administered with other myelosuppressive agents.
Bioavailability Restriction: Both a high-fat meal and Grapefruit Juice are documented to significantly increase the oral bioavailability and systemic exposure of Albendazole.
Population Note: Patients with pre-existing liver disease or elevated liver enzymes are formally noted to be at an increased risk for bone marrow suppression, a caution relevant to pharmacodynamic interactions.

Formal restrictions exist against use in patients with known hypersensitivity to the Benzimidazole class of compounds.

Mechanism of Action

The mechanism of action for Albezol (Albendazole) is purely pharmacodynamic, focusing on the targeted destruction of the parasitic organism through two interconnected cellular processes. The drug's activity is highly selective for parasitic cells.

Selective Targeting and Structural Collapse of Microtubules

The drug's active metabolite binds with high affinity to the beta-tubulin of the parasite. This interaction prevents the formation of microtubules, which are vital internal cellular structures. The resulting structural collapse causes rapid degenerative changes in the parasite's intestinal and tegmental cells, leading to functional failure.

Induction of Metabolic Starvation and Energy Failure

Following structural disruption, the loss of functional microtubules immediately blocks the organism's crucial ability to uptake and utilize glucose from the host. This energy deficit rapidly depletes the parasite's stored reserves, leading to metabolic collapse and subsequent immobilization, which is the physiological consequence leading to the death and subsequent elimination of the organism.

Dosage and Administration Information

How Albezol is Used: Official Administration Guidelines

Albezol (Albendazole) is strictly a prescription medicine used according to specific, standardized instructions. Adherence to these guidelines is essential for proper administration.

Route and Form

Albezol is administered exclusively by the oral route (by mouth). It is available as a tablet, chewable tablet, and oral suspension. For patients who cannot swallow the tablet whole, it may be crushed or chewed and then swallowed with water.

Dosage and Frequency

Dosing is based on the patient's body weight and is administered twice daily (BID). The maximum total daily dose should not exceed 800 mg.

Indication	Patient Weight	Standard Daily Dose and Frequency
Neurocysticercosis	≥ 60 kg	400 mg twice daily (BID)
	< 60 kg	15 mg/kg/day divided BID
Cystic Hydatid Disease	≥ 60 kg	400 mg twice daily (BID)
	< 60 kg	15 mg/kg/day divided BID

Administration Conditions and Duration

Food Requirement: Tablets must be taken with food, specifically a fatty meal, as this significantly enhances the drug's absorption.

Course Duration: The overall length of treatment is disease-specific:

Neurocysticercosis: The course duration ranges from 8 to 30 days.
Cystic Hydatid Disease: Treatment involves a cyclic regimen of 28 days of dosing followed by a 14-day drug-free interval, repeated for a total of three cycles.

Special Conditions: For females of reproductive potential, treatment should only be initiated after a negative pregnancy test has been confirmed. Dosing for pediatric patients is determined by the weight-based regimen for those under 60 kg.

Recent Clinical Evidence

Research evidence / Overview of Studies for Albezol

The clinical evidence for Albezol (Albendazole) is primarily derived from clinical studies and systematic reviews conducted worldwide used in research exploring parasitic infections. The research available, as summarized by regulatory authorities and scientific organizations, focuses on how the medicine was studied, what outcomes were measured, and where gaps in the evidence exist.

Evidence for Use in Neurocysticercosis

Research examining the use of Albezol for neurocysticercosis, a condition involving tapeworm cysts in the central nervous system, has relied on Randomized Controlled Trials (RCTs). Studies monitored specific measures of the changes observed during the study period.

Researchers primarily examined the status of the parasitic cysts and changes in clinical function. Cyst status was monitored using neuroimaging (CT or MRI scans) to monitor endpoints related to cyst status, including resolution, disappearance, or calcification. Clinical functioning was measured by monitoring endpoints related to systemic or functional imbalance, such as the frequency of generalized seizures.

Studies reported patterns where a greater proportion of participants had measures related to cyst disappearance compared to those who received supportive treatment without Albezol. Observational data collected over extended periods also described patterns where changes in seizure frequency were monitored in some populations studied.

Evidence for Use in Soil-Transmitted Helminth Infections

Albezol was evaluated in numerous large-scale clinical trials used in research exploring common soil-transmitted parasitic infections like roundworm (Ascaris lumbricoides) and hookworm. Research primarily examined short-term symptom changes, using standardized parasitological outcomes such as the Cure Rate (CR) and the Egg Reduction Rate (ERR).

Studies reported high measurements for the Cure Rate and Egg Reduction Rate for infections caused by roundworm and hookworm species. However, when the same regimens were studied for whipworm (Trichuris trichiura), the research consistently reported lower measurements for the Cure Rate.

Areas of Research Uncertainty and Study Gaps

Research provides context but not individual predictions, and the evidence highlights what is known and what is still uncertain. Limitations noted in the scientific literature include the following:

Evidence Quality Varies: For chronic conditions like cystic hydatid disease, the evidence quality varies, with a lack of large-scale RCTs for all cyst types or locations.
Limited Information for Long-Term Outcomes: For chronic parasitic diseases, the slow nature of cyst resolution means that long-term effects are not fully established, and follow-up durations were limited in some key studies.
Subgroup Findings Are Uncertain: Efficacy is consistently reported as lower for Trichuris trichiura infection compared to other parasitic worms, and data for this specific subgroup remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Albezol (FAQ)

Q: Does Albezol have a generic version available under a different name?

A: Yes. The official product information confirms that the active ingredient in Albezol is albendazole. Albendazole is available as a generic medicine.

Q: Is Albezol a commonly prescribed drug, or is it reserved for specific cases?

A: The World Health Organization (WHO) includes the active ingredient on its Model List of Essential Medicines. This designation indicates its established role and significance in global public health for treating various parasitic diseases.

Q: How quickly does Albezol start to work after the first time taking it?

A: Official pharmacokinetic data shows that the drug's active form typically reaches its highest concentration in the blood within two to five hours after being absorbed. However, the observable therapeutic effect depends on the specific disease being examined and is not immediate upon absorption.

Q: How will I know if Albezol is actually working for my condition?

A: The effects of the medicine are primarily tracked using clinical and imaging endpoints in formal studies. For conditions like neurocysticercosis, researchers monitored the resolution or disappearance of parasitic cysts using brain scans and tracked changes in functional measures, such as the frequency of seizures.

Q: Are there any specific vitamins, minerals, or supplements to avoid while on Albezol?

A: Regulatory documents specifically note that the consumption of grapefruit juice can significantly increase the concentration of the drug in the body. Consultation with a health professional regarding the use of any vitamins, minerals, or other supplements while on this treatment is recommended.

Q: Does Albezol interact with birth control pills?

A: The official drug label notes the requirement for women of childbearing potential to use effective contraception during and after therapy. Some regulatory warnings also reference the co-administration of oral contraceptives, as the drug's metabolism has been shown to affect other substances in the body.

Q: Does Albezol affect driving or operating machinery?

A: Adverse reactions such as dizziness or vertigo have been reported by some patients taking the medicine. Official labels state that caution may be warranted if these effects occur while performing tasks that require concentration, such as driving or operating machinery.

Q: How soon after stopping Albezol do the side effects usually go away?

A: Official safety information indicates that the common, reversible elevation of liver enzymes often returns to normal levels upon discontinuation of the medicine. The duration for other potential side effects to resolve may vary, and a specific timeline for all adverse reactions is not provided.

Q: Are the side effects generally worse at the beginning of the treatment course?

A: For patients treated for neurocysticercosis, official safety information notes that certain neurological symptoms, like an increase in pressure around the brain, may appear soon after treatment initiation. Official documents describe this change as related to the inflammatory response that may occur when the parasites begin to die.

Q: Is hair loss a common side effect of Albezol treatment?

A: Reversible alopecia, which is the medical term for hair loss, is listed in official documents as an adverse reaction. Studies for one specific indication (Hydatid Disease) observed this effect in a small percentage of treated patients.

Q: What is the likelihood of having a serious, but rare, side effect like bone marrow suppression?

A: The official product information describes bone marrow suppression as a rare, but serious, documented adverse reaction. Regulatory documents indicate that occasional, reversible reductions in white blood cell counts may occur in a small percentage of treated patients. Regular monitoring of blood cell counts is required during therapy to help detect these changes early.

Q: What is the purpose of the routine check-ups and monitoring while on this medicine?

A: Official regulatory information requires mandatory, frequent monitoring of certain laboratory values during treatment. The purpose of checking liver enzymes and blood cell counts is to detect early signs of serious, but rare, side effects such as hepatotoxicity (liver damage) and bone marrow suppression.

Q: Are there known effects of Albezol on mental clarity or concentration?

A: While there are no direct claims about mental clarity in the safety labels, some documented adverse reactions may indirectly impact concentration. Official safety information lists effects such as headache, dizziness, and, for specific conditions like neurocysticercosis, raised intracranial pressure.

How should Albezol be stored and disposed of?

How to Store and Dispose of Albezol?

Albezol (Albendazole) must be stored and discarded according to specific instructions found in its official regulatory labeling to ensure product stability and environmental safety.

Official Storage Conditions

Condition	Requirement
Temperature	Store at controlled room temperature, typically below 30 C (86 F); do not freeze the medicine.
Protection	Keep the medicine out of the sight and reach of children and store it protected from excess heat and moisture.
Packaging	Keep the medication in the container it came in and ensure it is tightly closed at all times.

Disposal Instructions

Official regulations prohibit disposing of unused or expired Albezol by pouring it down a drain or throwing it into household trash. The active ingredient is classified as very toxic to aquatic life, requiring disposal to comply strictly with local requirements or authorized pharmaceutical take-back programs.

Albezol